Cardiomyopathy Registry Study-II (CARS-II): Dilated cardiomyopathy in children. Improving diagnosis by state-of-the-art genotyping and outcome by risk stratification and by optimizing pharmacotherapy

Cardiomyopathy Registry Study-II (CARS-II): Dilated cardiomyopathy in children. Improving diagnosis by state-of-the-art genotyping and outcome by risk stratification and by optimizing pharmacotherapy - Heartfailure in children with cardiomyopathy in children-2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40498

Enrollment

140

Registered

2014-05-28

Start date

2014-08-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiomyopathy heart muscle disease

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Children with dilated cardiomyopathy

Exclusion criteria

Exclusion criteria: inabilty to cooperate with the study protocol (i.e mental retardation) For specific procedures within the protocol general accepted contra-indications may apply. Specifiically, for MRI the presence of MRI incompatible materials in the body and for the application of contrast because of renal impairment.

Design outcomes

Primary

Measure	Time frame
Differences in clinical (eg laboratory parameters, echocardiogram, ECG, Quality of life) and genetic profile between patients reaching perimary endpoint (death of harttransplantation) and those who do not reach an endpoint. PK data of Milrinone, Enalapril en Carvedilol Genetic profile of all idiopathic DCM pediatric patients (including whole exome sequencing and mutations in non-coding DNA regulatory elements)	—

Measure

Time frame

Differences in clinical (eg laboratory parameters, echocardiogram, ECG, Quality of life) and genetic profile between patients reaching perimary endpoint (death of harttransplantation) and those who do not reach an endpoint. PK data of Milrinone, Enalapril en Carvedilol Genetic profile of all idiopathic DCM pediatric patients (including whole exome sequencing and mutations in non-coding DNA regulatory elements)

—

Secondary

Measure	Time frame
listing for heart transplantation, hospitalization for worsening heart failure, hospitalization for all causes	—

Countries

Netherlands

Outcome results